Cytokine Release Syndrome Market expected to rise, DelveInsight | Companies such as Novartis, Incyte Corporation, Olatec Therapeutics LLC, expected to drive market

The Cytokine Release Syndrome market growth is driven by factors like increase in the prevalence of Cytokine Release Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Cytokine Release Syndrome market report [https://www.delveinsight.com/report-store/cytokine-release-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Cytokine Release Syndrome market size, share, Cytokine Release Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Cytokine Release Syndrome market size growth forward.

Some of the key highlights from the Cytokine Release Syndrome Market Insights Report:

*
Cytokine Release Syndrome (CRS) is a severe systemic inflammatory response often triggered by treatments like CAR T-cell therapy, therapeutic antibodies, and haploidentical allogeneic transplants. It is typically characterized by symptoms such as fever and multi-organ dysfunction.

*
The United States holds the largest share (85%) of the CRS treatment market, compared to the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

*
Currently, ACTEMRA (tocilizumab) is the only approved therapy for CRS, although treatment often relies on off-label drugs. Several companies are actively investigating new treatment options, with key players like Incyte Corporation (with Itacitinib), Sobi Pharma (with Kineret), and others conducting clinical trials aimed at improving CRS management.

*
Among the emerging therapies, Itacitinib is anticipated to capture the largest market share by 2034 across the 7MM.

*
According to DelveInsight analysts, the majority of CRS cases (approximately 80% in 2023) are associated with allogeneic transplants in the 7MM.

Strategise your business goals by understanding market dynamics @ Cytokine Release Syndrome Market Landscape [https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Cytokine Release Syndrome Overview

Cytokine Release Syndrome (CRS) is a systemic inflammatory response triggered by various factors, including infections and certain drugs, leading to the pathological over-activation of T cells. This, in turn, causes excessive cytokine release from T cells and other immune cells. CRS can also arise after certain immunotherapies, such as CAR T-cell therapy, and is sometimes referred to as a "cytokine storm" or "cytokine-associated toxicity." Clinically, CRS is characterized by fever and malaise, which can progress quickly to capillary leak syndrome, hypotension, vasodilatory shock, hypoxia, and potentially death. The severity of CRS can vary, ranging from mild constitutional symptoms to a severe form that involves multi-organ dysfunction.

Currently, there are no established diagnostic criteria for CRS. An accurate diagnosis typically relies on three key elements: clinical symptoms, elevated biomarkers, and recent treatment with biological agents. While circulating cytokine levels could be used as biomarkers to diagnose and assess the severity of CRS, these tests are often costly and may not be readily available in all healthcare settings. C-reactive protein (CRP), produced by the liver in response to interleukin-6 (IL-6), is a reliable surrogate marker for IL-6 bioactivity. Measuring CRP is inexpensive, quick, and widely available, making it a practical tool for diagnosing and monitoring CRS in most hospitals.

This report on Cytokine Release Syndrome offers an in-depth overview of the pathophysiology, diagnostic approaches, and treatment algorithms for CRS. It also includes a real-world patient journey, detailing the progression from initial symptoms to diagnosis and treatment.

There is strong evidence suggesting that interleukin-6 (IL-6), which exhibits both anti-inflammatory and pro-inflammatory properties, plays a crucial role as a mediator in the signaling cascade of Cytokine Release Syndrome (CRS). In addition to its role in CRS, IL-6 may also be involved in initiating the body's antitumor response.

In August 2017, the U.S. FDA approved ACTEMRA (tocilizumab) for the treatment of severe or life-threatening CRS induced by CAR T-cell therapy in patients aged 2 years and older. ACTEMRA is a humanized monoclonal antibody that acts as an IL-6 receptor antagonist, blocking both classic and trans-IL-6 signaling pathways on immune effector cells.

IL-6 has emerged as a key cytokine in exacerbating CRS, particularly in T-cell-engaging therapies. Depending on the clinical setting, both tocilizumab (an IL-6 receptor-targeting monoclonal antibody) and siltuximab (a chimeric anti-IL-6 monoclonal antibody) are used to manage CRS. In cases where toxicities are refractory to IL-6-targeting therapies, corticosteroids are often introduced. Typically, dexamethasone (10 mg/kg IV every 6 hours) or methylprednisolone (1 mg/kg IV every 12 hours) are administered for moderate to high-grade CRS.

Do you know the treatment paradigms for different countries? Download our Cytokine Release Syndrome Market Sample Report [https://www.delveinsight.com/report-store/cytokine-release-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Cytokine Release Syndrome Epidemiology Insights:

*
In 2023, DelveInsight estimates that approximately 30% of the total Cytokine Release Syndrome (CRS) cases in the 7MM occurred in the United States.

*
Of the CRS cases in the United States, around 30% were attributed to treatments involving CAR-T therapies.

*
Grade 3-4 CRS cases accounted for approximately 18% of the total incident CRS cases in the 7MM in 2023, according to DelveInsight's consultant estimates.

*
Among the EU4 countries and the UK, Germany reported the highest incidence of CRS cases, followed by France.

Cytokine Release Syndrome Epidemiology Segmentation

DelveInsight's Cytokine Release Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Cytokine Release Syndrome historical patient pools and forecasted Cytokine Release Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Cytokine Release Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Cytokine Release Syndrome Prevalence

*
Age-Specific Cytokine Release Syndrome Prevalence

*
Gender-Specific Cytokine Release Syndrome Prevalence

*
Diagnosed and Treatable Cases of Cytokine Release Syndrome

Visit for more @ Cytokine Release Syndrome Epidemiological Insights [https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Cytokine Release Syndrome Market Insights:

*
The United States accounts for approximately 85% of the Cytokine Release Syndrome (CRS) market, surpassing the combined market size of the EU4, the UK, and Japan.

*
Among emerging therapies, Itacitinib is projected to capture the largest market share (51%) by 2034 across the 7MM.

*
According to DelveInsight's forecasts, Germany is expected to hold the second-largest market share for CRS treatment during the 2024-2034 period.

Cytokine Release Syndrome Treatment Market

The Cytokine Release Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cytokine Release Syndrome market trends by analyzing the impact of current Cytokine Release Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Cytokine Release Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cytokine Release Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cytokine Release Syndrome market in 7MM is expected to witness a major change in the study period 2020-2034.

Cytokine Release Syndrome Key Companies

*
Novartis

*
Incyte Corporation

*
Olatec Therapeutics LLC

*
And others

Cytokine Release Syndrome Pipeline Therapies

*
Canakinumab

*
Itacitinib

*
Dapansutrile

*
And others

Cytokine Release Syndrome Pipeline Analysis: Drug Profile

Canakinumab: Novartis

Canakinumab is an interleukin (IL)-1 blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis. Novartis is conducting a phase III trial, called CAN-COVID which will evaluate the drug's efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.

For more information, visit Cytokine Release Syndrome Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/cytokine-release-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Cytokine Release Syndrome Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Cytokine Release Syndrome, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Cytokine Release Syndrome epidemiology in the 7MM

*
Cytokine Release Syndrome marketed and emerging therapies

*
Cytokine Release Syndrome companies

*
Cytokine Release Syndrome market drivers and barriers

Key Questions Answered in the Cytokine Release Syndrome Market Report 2034:

*
What was the Cytokine Release Syndrome market share distribution in 2020, and how would it appear in 2034?

*
What is the total Cytokine Release Syndrome market size and the market size by therapy across the 7MM for the study period (2020-32)?

*
What are the important findings from 7MM, and which country will have the greatest Cytokine Release Syndrome market size from 2020-32?

*
During the study period (2020-2034), at what CAGR is the Cytokine Release Syndrome market projected to expand at 7MM?

Table of Contents:

1 Cytokine Release Syndrome Market Key Comprehensive Insights

2 Cytokine Release Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Cytokine Release Syndrome

4 Cytokine Release Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Cytokine Release Syndrome

6 Cytokine Release Syndrome Epidemiology and Market Methodology

7 Cytokine Release Syndrome Epidemiology and Patient Population

8 Cytokine Release Syndrome Patient Journey

9 Cytokine Release Syndrome Treatment Algorithm, Cytokine Release Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Cytokine Release Syndrome Clinical Trials

11 Cytokine Release Syndrome Marketed Therapies

12 Cytokine Release Syndrome Emerging Therapies

13 Cytokine Release Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Cytokine Release Syndrome

16 Cytokine Release Syndrome Market Key Opinion Leaders Reviews

18 Cytokine Release Syndrome Market Drivers

19 Cytokine Release Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Cytokine Release Syndrome Epidemiology 2034

DelveInsight's "Cytokine Release Syndrome - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Cytokine Release Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cytokine Release Syndrome Pipeline 2023

"Cytokine Release Syndrome Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cytokine Release Syndrome market. A detailed picture of the Cytokine Release Syndrome pipeline landscape is provided, which includes the disease overview and Cytokine Release Syndrome treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cytokine-release-syndrome-market-expected-to-rise-delveinsight-companies-such-as-novartis-incyte-corporation-olatec-therapeutics-llc-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.